User Profile
Corporate
Careers
FAQ
Blog
Pricing
Social
General Modals
Advanced Modals
Search
Wizards
Expression of interest: Prosperity partnerships: advanced therapies safety and toxicity
Toxicity issues with advanced therapies (ATs) include, but are not limited to, immune reactions, off-target gene effects, and tumourigenesis. The long-term safety of many advanced therapies remains uncertain, with potential for unexpected toxic effects over time.
Therefore, advancing our understanding of how these therapies can be safely and effectively delivered to patients holds significant potential for breakthroughs, particularly in treating complex and previously untreatable conditions.
This funding opportunity aims to establish core resources and capabilities in advanced therapy toxicology for the UK, fostering connectivity among business, academia, and regulatory bodies, and gaining insights into the biological processes through which ATs can cause harm.
Research into the toxicity of advanced therapies, including the advanced therapy medicinal product (ATMP) classification of cell and gene therapies, regenerative medicine and nucleic acid therapies such as oligonucleotide base therapies and base or gene editing techniques, are all in scope.
Aims include modelling short and long-term adverse effects and translating research evidence into harmonised standards and definitions of future regulatory pathways. Additionally, this initiative aims to influence policy and standards in the AT sector and support skills and training in toxicology and regulatory science.
Prosperity partnerships should aim to address at least one of the following challenge areas in at least one area of advanced therapies:
- mechanisms governing safety and toxicology of ATs
- persistence, localisation and distribution of ATs in vivo
- translation of mechanistic insights into tools and assays, and development of a standardised approach to assessment of safety and toxicology of ATs
For more information on these three challenge areas see the Additional information section.
Prosperity partnerships funded through this initiative will be co-developed with academia and business addressing significant challenge areas in safety and toxicology. These partnerships will form a UK-wide network that goes beyond the individual partnerships, coalescing the field and providing both connectivity and critical mass.
The strategic partnership can be newly established or based on existing, long-term relationships. It should be recognised by both parties and have a clear path for future collaboration, possibly formalised by a memorandum of understanding (MoU) or a collaboration agreement.
The research programme must be co-created, driving shared research challenges, with both business and academic researchers making distinct intellectual contributions.
This is an expression of interest stage, and the information about the full application stage may change. You can only apply for the full funding opportunity if we have invited you to do so following a successful expression of Interest.
Specialties
Eligibility Requirements
Research organisations can act as the academic lead if they are eligible to receive UKRI funding.
Businesses can act as the lead project partner if they are:
- a UK-based business or have UK-based research activity
- a business in the private sector driven by profit, or from an organisation with a commercial arm which generates independent revenue
- able to contribute to the UK national prosperity through increasing their investment in research and development activities and subsequent product, service, or technology development in the UK
Businesses may be a contributor to other applications as a project partner. Other businesses can collaborate in the partnership as project partners, but the majority of the matched contribution is expected from the lead business partner.
Before applying for funding, check the Eligibility of your organisation.
UKRI has introduced new role types for funding opportunities being run on the new Funding Service.
For full details, visit Eligibility as an individual.
A research organisation may lead or partner on more than one application and applications may comprise more than one research organisation.
For applicants who do not have a contract of employment for the duration of the proposed programme, by submitting an application the research organisation is confirming, if it is successful:
- contracts will be extended beyond the end date of the programme
- all necessary support for the programme and the applicants will be provided, including mentorship and career development for early career researchers
Who is not eligible to apply
You are not eligible to apply for this opportunity as academic lead if you are based at an international research organisation. This does not include MRC Unit The Gambia or MRC/UVRI Uganda Research Unit at the London School of Hygiene and Tropical Medicine that are eligible to apply as project lead. Before applying for funding, check the Eligibility of your organisation.
International applicants
You can include international applicants as project co-leads (international), where they will make a major intellectual contribution to the design or conduct of the programme. The contribution and added value to the research collaboration should be clearly explained and justified in the application.
Equality, diversity and inclusion
We are committed to achieving equality of opportunity for all funding applicants. We encourage applications from a diverse range of researchers.
We support people to work in a way that suits their personal circumstances. This includes:
- career breaks
- support for people with caring responsibilities
- flexible working
- alternative working patterns
Eligible Countries:
Sponsor Details
Sponsor Institute/Organizations: UK Research and Innovation
Address: UKRI, 1 ET, Polaris House, N Star Ave, Swindon SN2 1FL, United Kingdom
Legal & Affiliation Disclaimer
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Grant
Letter Of Intent Deadline:
Nov 06, 2024
Final Deadline:
Feb 12, 2025
Funding Amount:
$2,626,400
5 awards available. Award range: £2,000,000 - £4,000,000
Host Details
Affiliation: UK Research and Innovation
Address: UKRI, 1 ET, Polaris House, N Star Ave, Swindon SN2 1FL, United Kingdom
Website URL: https://www.ukri.org/opportunity/prosperity-partnerships-advanced-therapies-safety-and-toxicity/
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.
Invite Gmail Contacts